gosogliptin
Small moleculeexperimental
Gosogliptin is a drug for the treatment of type II diabetes. It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It was discovered and developed through Phase 1 and Phase 2 by Pfizer. The crystal structure of DPP-4 in complex with gosogliptin is available. Its metabolism, excretion and pharmacokinetics in rat, dog and human have been described. A cost efficient route has been published. Other studies including Phase 3 studies were conducted in Russia. It is approved for use in Russia. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2007 (NCT00473525)
Timeline
Indications
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1- Mol. weight
- 366.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaGosogliptin ↗
- ChEMBLCHEMBL515387 ↗
Also known as
- 2-(4-{(3s,5s)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine
- 2-(4-{(3s,5s)-5-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-3-yl}piperazin-1-yl)pyrimidine
- gosogliptin
- gosogliptin
- gosogliptin
- gosogliptin
- gosogliptin
- pf-00734200
- pf-00734200
- pf-00734200
- pf-00734200
- pf-734200
- pf-734200
- pf-734200
- pf-734,200
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03088670 | Phase 3 | Apr 23, 2013 | SatRx LLC |
| NCT00618007 | Phase 2 | Feb 1, 2008 | Pfizer |
| NCT00596518 | Phase 1 | Oct 1, 2007 | Pfizer |
| NCT00473525 | Phase 2 | Jul 1, 2007 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1